Fluorescentiemicroscoo_Vision

Visualization of tissue with molecular imaging 

Using molecular targeted tracers, we enable visualization and identification of tissue and biodistribution of molecules in the near-infrared spectrum.
Do you want to get in touch?

Milestones

First in-human results

In 2011 our research group performed the first in-human fluorescence study concerning intraoperative staining of ovarian cancer.

Read more
eerste publ

First spectroscopy study

The TRACT-I was the first study that utilized NIR spectroscopy in rectal cancer patients using Bevacizumab-IRDye800CW.

Read more
Tract spectro 2_bewerkt

First endoscopic study

In 2014 the first study started using systemic and topical administration of a fluorescence-labelled antibody against vascular endothelial growth factor (VEGF) utilizing a NIR infrared camera system.

Read more
SharedScreenshot

First Head and Neck Cancer study

Start of ICON study; the first Head and Neck Cancer study at OMIG. The ICON study is a clinical trial for the intraoperative assessment of tumor margins during surgical treatment using cetuximab-IRDye800CW

Read more

Start of Thyroid TARGET study

The Thyroid Cancer Target study is a dual study. The first part started in 2018, using EMI-137 in targeting thyroid cancer. The second part started in 2021, utilizing Bevacizumab-IRDye800CW.

Read more
Afbeelding1

Start of first IBD study

The VISION study is the first study that focussed on IBD pathology. In this study Vedolizumab-800CW is utilized to identify inflamed gut mucosa using near-infrared fluorescence molecular endoscopy (NIR-FME), spectroscopy and confocal laser endomicroscopy (CLE).

Read more
All team members
- Prof. Dr. Wouter Nagengast, Gastroenterologist
- Prof. Dr. Max Witjes , head and neck surgical oncologist
- Prof. Dr. Schelto Kruijff, Oncological and endocrine surgeon
Wouter lachend
IMG_8141
IMG_8217

We are working with...

All our partners